Furthermore, using a GMP-grade version of those F3-peptide-targeted liposomes (named PEGASEMP), it was demonstrated that shifting from the cancer-cell-targeting paradigm towards exploiting readily accessible overexpressed nucleolin at the tumor vasculature, enabling cell internalization, provided a significant improvement in the intratumor bioavailability of the delivered drug, at a lower, but safer, systemic exposure than Caelyx/Doxil [19]. The gene discussed is NUCLEOLIN; the disease is neoplasm.